FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products

The FDA issued warning letters to two companies this month, alleging FD&C Act violations stemming from marketing new drugs without approval. Companies marketing CBD products should be careful not to market OTC drugs containing CBD.

The post FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products appeared first on Cannabis Industry Journal.

Jazz Pharmaceuticals to Acquire GW Pharma

In a press release published last week, the two companies announced they have entered an agreement for Jazz to acquire GW Pharma, the producer of the only FDA-approved CBD medication Epidiolex, for a total of $7.2 billion.

The post Jazz Pharmaceuticals to Acquire GW Pharma appeared first on Cannabis Industry Journal.

AOAC Approves New Microbial Testing Validations

bioMérieux just received the first AOAC validation approval for cannabis and hemp. AOAC approved the detection of Salmonella and STEC (Shiga toxin-producing E. coli) utilizing two bioMérieux assays.

The post AOAC Approves New Microbial Testing Validations appeared first on Cannabis Industry Journal.

AOAC Approves New Microbial Testing Validations

bioMérieux just received the first AOAC validation approval for cannabis and hemp. AOAC approved the detection of Salmonella and STEC (Shiga toxin-producing E. coli) utilizing two bioMérieux assays.

The post AOAC Approves New Microbial Testing Validations appeared first on Cannabis Industry Journal.